Hypha Labs Provides Shareholder Update
Hypha Labs (OTCQB:FUNI), an AI-powered functional mushroom company, provided a shareholder update highlighting significant developments. The company is finalizing its patent-pending Mushroom Accelerator technology, which enables mushroom cultivation in approximately eight days on a kitchen counter.
The update emphasizes the expanding market opportunity amid favorable regulatory changes for psilocybin. Notable developments include New Mexico becoming the third state to legalize medical psilocybin, joining Oregon and Colorado. The functional mushroom market is projected to grow from $33 billion in 2025 to $62 billion by 2032. CEO Stone Douglass expressed optimism about the company's position to capitalize on potential regulatory changes in the psychedelic therapeutics sector.
Hypha Labs (OTCQB:FUNI), un'azienda specializzata in funghi funzionali potenziati dall'intelligenza artificiale, ha fornito un aggiornamento agli azionisti evidenziando sviluppi significativi. L'azienda sta completando la sua tecnologia Mushroom Accelerator, attualmente in fase di brevetto, che permette la coltivazione di funghi in circa otto giorni direttamente sul piano della cucina.
L'aggiornamento sottolinea le crescenti opportunità di mercato grazie a cambiamenti normativi favorevoli per la psilocibina. Tra gli sviluppi più importanti vi è il fatto che il New Mexico è diventato il terzo stato a legalizzare la psilocibina medica, unendosi a Oregon e Colorado. Il mercato dei funghi funzionali è previsto in crescita da 33 miliardi di dollari nel 2025 a 62 miliardi entro il 2032. Il CEO Stone Douglass si è mostrato ottimista riguardo alla posizione dell'azienda per sfruttare eventuali cambiamenti normativi nel settore delle terapie psichedeliche.
Hypha Labs (OTCQB:FUNI), una empresa de hongos funcionales impulsada por inteligencia artificial, proporcionó una actualización para accionistas destacando desarrollos significativos. La compañía está finalizando su tecnología Mushroom Accelerator, pendiente de patente, que permite cultivar hongos en aproximadamente ocho días sobre una encimera de cocina.
La actualización resalta la creciente oportunidad de mercado en medio de cambios regulatorios favorables para la psilocibina. Entre los desarrollos notables está que Nuevo México se convirtió en el tercer estado en legalizar la psilocibina médica, uniéndose a Oregón y Colorado. Se proyecta que el mercado de hongos funcionales crezca de
Hypha Labs (OTCQB:FUNI)는 인공지능 기반 기능성 버섯 회사로서 주주들에게 중요한 발전 사항을 알리는 업데이트를 제공했습니다. 회사는 주방 조리대에서 약 8일 만에 버섯을 재배할 수 있는 특허 출원 중인 Mushroom Accelerator 기술을 마무리하고 있습니다.
이번 업데이트는 실로시빈에 대한 우호적인 규제 변화 속에서 확장되는 시장 기회를 강조합니다. 주목할 만한 발전으로는 뉴멕시코가 의료용 실로시빈을 합법화한 세 번째 주가 되었다는 점으로, 오리건과 콜로라도에 이어진 것입니다. 기능성 버섯 시장은 2025년 330억 달러에서 2032년 620억 달러로 성장할 것으로 예상됩니다. CEO 스톤 더글라스는 정신치료제 분야의 잠재적 규제 변화에 대응할 회사의 입장에 대해 낙관적인 입장을 밝혔습니다.
Hypha Labs (OTCQB:FUNI), une entreprise spécialisée dans les champignons fonctionnels propulsée par l'intelligence artificielle, a fourni une mise à jour aux actionnaires mettant en lumière des développements importants. L'entreprise finalise sa technologie Mushroom Accelerator, en attente de brevet, qui permet la culture de champignons en environ huit jours sur un plan de travail de cuisine.
La mise à jour souligne l'opportunité croissante du marché dans un contexte de changements réglementaires favorables pour la psilocybine. Parmi les développements notables, le Nouveau-Mexique est devenu le troisième État à légaliser la psilocybine médicale, rejoignant l'Oregon et le Colorado. Le marché des champignons fonctionnels devrait passer de 33 milliards de dollars en 2025 à 62 milliards d'ici 2032. Le PDG Stone Douglass s'est montré optimiste quant à la position de l'entreprise pour tirer parti des éventuels changements réglementaires dans le secteur des thérapies psychédéliques.
Hypha Labs (OTCQB:FUNI), ein auf KI basierendes Unternehmen für funktionelle Pilze, gab ein Aktionärs-Update mit bedeutenden Entwicklungen bekannt. Das Unternehmen finalisiert seine zum Patent angemeldete Mushroom Accelerator-Technologie, die die Pilzzucht in etwa acht Tagen auf einer Küchenarbeitsplatte ermöglicht.
Das Update hebt die wachsenden Marktchancen hervor, die sich durch günstige regulatorische Veränderungen für Psilocybin ergeben. Zu den bemerkenswerten Entwicklungen gehört, dass New Mexico der dritte Bundesstaat wurde, der medizinisches Psilocybin legalisiert, nach Oregon und Colorado. Der Markt für funktionelle Pilze wird voraussichtlich von 33 Milliarden US-Dollar im Jahr 2025 auf 62 Milliarden US-Dollar bis 2032 wachsen. CEO Stone Douglass zeigte sich optimistisch hinsichtlich der Position des Unternehmens, um von potenziellen regulatorischen Änderungen im Bereich psychedelischer Therapien zu profitieren.
- Development of innovative patent-pending Mushroom Accelerator technology for rapid cultivation
- Expanding market opportunity with functional mushroom market projected to grow from $33B (2025) to $62B (2032)
- Favorable regulatory environment with increasing state-level psilocybin legalization
- Strategic positioning to capitalize on potential deregulation in psychedelic therapeutics
- Product not yet launched in the market
- Ongoing engineering and testing phase causing delay in market entry
- Operating in a highly regulated industry with uncertain timeline for broader legalization
LAS VEGAS, NEVADA / ACCESS Newswire / July 28, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), an Artificial Intelligence (AI) powered pioneer in functional mushroom sciences and the creator of the MicroPearls™ suite of products, is pleased to provide a shareholder update from its Chief Executive Officer, Stone Douglass.
Greetings,
While we have been quiet of late we have not been idle, and I am pleased to offer this brief update for your consideration. When you are at the helm of a Company which I firmly believe will soon transform an industry there are many, many moving pieces to consider, both within our revolutionary device and the market in front of us.
I am pleased and optimistic about what I see inside our laboratory and beyond our doors.
Our team continues to persevere to perfect our patent-pending Mushroom Accelerator which allows for a splendid crop of mushrooms to be cultivated on a kitchen counter in about eight days. Because you get only one first impression, our engineers are constantly testing, innovating, and evaluating so that when we go-to-market we do so with our best. Expect more communication about all this very, very soon.
And as we endeavor in our white coats ever mindful of the opportunity, we see that opportunity expanding perhaps exponentially. Recent events now align to some extent government and public views in favor of the magic of the mushroom.
These are no small movements.
Recent developments across the United States signal growing momentum for psilocybin legalization and therapeutic use. In April 2025, New Mexico became the third state to legalize medical psilocybin, joining Oregon and Colorado. The new law targets treatment-resistant conditions such as PTSD, depression, and end-of-life anxiety, and establishes a regulatory advisory board to oversee implementation. Meanwhile, the Iowa House passed a similar medical psilocybin bill, which now moves to the Senate for further debate. Colorado also made headlines this spring by issuing its first psilocybin therapy training credits and preparing to launch a statewide licensing program for healing centers by year's end.
At the federal level, President Trump's nominee for U.S. Surgeon General, Dr. Casey Means, has publicly praised guided psilocybin therapy, citing both clinical benefits and personal experience. Several U.S. cities-including Tacoma, Washington-have also moved to decriminalize natural psychedelics in recent months. Meanwhile, public interest continues to rise, with studies showing that adult use of psilocybin has doubled since 2019. As legal frameworks expand and public acceptance grows, these milestones reflect a transformative moment for mental health care and the future of psychedelic therapeutics.
We intend to be ready and able to support any potential regulatory changes that could usher a massive shift in the way consumers obtain all functional mushrooms. The existing functional mushroom market as it stands (
Sincerely,
Stone Douglass
Chief Executive Officer
About Hypha Labs, Inc.
The company has developed revolutionary, cutting-edge technology focused on new methods of producing the active ingredients found in a wide array of functional mushrooms using its patent-pending mushroom accelerators. The Company is positioning itself to play an important role in the burgeoning Functional Mushroom industry in addition to being a disruptive force in future and emerging mushroom opportunities. Visit us at HyphaLabs.com.
SAFE HARBOR FORWARD LOOKING STATEMENTS:
This press release may contain forward looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
From time to time, the Company may post new and material information on its website or through its social media profiles at the links below:
LN: https://www.linkedin.com/company/hypha-labs-inc/
FB: https://www.facebook.com/hyphalabs
IG: https://www.instagram.com/hyphalabsinc/
Twitter: https://x.com/Hypha_Labs
For more information about Hypha Labs visit HyphaLabs.com
For the Company's current Investor Presentation please visit www.HyphaLabs.com/deck
Investor and Media Relations:
Integrity MediaInc.
(888) 216-3595
team@integritymedia.com
SOURCE: Hypha Labs, Inc.
View the original press release on ACCESS Newswire
FAQ
What is Hypha Labs' (OTCQB:FUNI) main product development?
What is the projected market size for functional mushrooms by 2032?
Which states have legalized medical psilocybin as of 2025?
How is the regulatory landscape changing for psilocybin in the United States?
When will Hypha Labs launch its Mushroom Accelerator product?
